Kelley Lauren Coffman, MD, Responses to and Adverse Effects of Therapy With 177Lu-DOTATATE in Well-Differentiated, High-Grade NETs

Video

The hospitalist at Memorial Sloan Kettering Cancer Center discussed the results of a study which evaluated the use of 177Lu-DOTATATE in patients with well-differentiated, high-grade neuroendocrine tumors.

Investigators observed a meaningful disease control rate among patients with well-differentiated, high-grade neuroendocrine tumors (NETs) who were treated with 177Lu-DOTATATE (Lutathera), according to study results presented at the 2021 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium.

In an interview with CancerNetwork®, Kelley Lauren Coffman, MD, a hospitalist at Memorial Sloan Kettering Cancer Center, spoke about the results of the study and the toxicities she and her colleagues observed during the trial.

Transcription:

In the predominant results, we saw that there was good benefit in terms of disease stability from the treatment. About 63% of patients had a partial response to the therapy after completing 4 cycles, about 6% had stable disease, and unfortunately about a third of the patients, about 31%, did progress.

The other notable results were the toxicities. It was consistent with what was seen in the earlier trials, where the primary toxicity was bone marrow suppression and [aspartate aminotransferase; AST]/[alanine aminotransferase; ALT] elevation. But the severity in our patient population was not quite that high. We didn’t really see any grade 3 or grade 4 toxicities.

Reference:

Coffman KL, Bodei L, Le T, et al. Treatment response and clinical outcomes of well-differentiated high-grade neuroendocrine tumors to 177Lu-DOTATATE. J Clin Oncol. 2021;39(suppl 3). Abstract #: 368.

Related Videos
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
There is no absolute age cutoff where CAR T cells are contraindicated for those with large B-cell lymphoma, says David L. Porter, MD.
David L. Porter, MD, emphasizes referring patients with large B-cell lymphoma early for CAR T-cell therapy consultation.